ID: ALA5203890

Max Phase: Preclinical

Molecular Formula: C17H17ClN6O

Molecular Weight: 356.82

Associated Items:

Representations

Canonical SMILES:  O=C(Nc1cccc2cn[nH]c12)N1CCN(c2ncccc2Cl)CC1

Standard InChI:  InChI=1S/C17H17ClN6O/c18-13-4-2-6-19-16(13)23-7-9-24(10-8-23)17(25)21-14-5-1-3-12-11-20-22-15(12)14/h1-6,11H,7-10H2,(H,20,22)(H,21,25)

Standard InChI Key:  GLYANQAZHKCPSU-UHFFFAOYSA-N

Associated Targets(Human)

Vanilloid receptor 8273 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 356.82Molecular Weight (Monoisotopic): 356.1152AlogP: 2.97#Rotatable Bonds: 2
Polar Surface Area: 77.15Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 10.49CX Basic pKa: 4.70CX LogP: 2.37CX LogD: 2.37
Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.74Np Likeness Score: -2.39

References

1. Liang Q, Qiao Z, Zhou Q, Xue D, Wang K, Shao L..  (2022)  Discovery of Potent and Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Agonists with Analgesic Effects In Vivo Based on the Functional Conversion Induced by Altering the Orientation of the Indazole Core.,  65  (17.0): [PMID:36008373] [10.1021/acs.jmedchem.2c00469]

Source